Periventricular Magnetisation Transfer Ratio Abnormalities in Multiple Sclerosis Improve After Alemtuzumab

Multiple Sclerosis - United States
doi 10.1177/1352458519852093
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

SAGE Publications

Related search

Regional Patterns of Grey Matter Atrophy and Magnetisation Transfer Ratio Abnormalities in Multiple Sclerosis Clinical Subgroups: A Voxel-Based Analysis Study

Multiple Sclerosis
Neurology
2014English

Immune Competence After Alemtuzumab Treatment of Multiple Sclerosis

Neurology
Neurology
2013English

A Case of Autoimmune Myositis After Treatment With Alemtuzumab for Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2018English

Sleep Abnormalities in Multiple Sclerosis

Current Treatment Options in Neurology
Neurology
2019English

Alemtuzumab Following Natalizumab in Highly Active Paediatric-Onset Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Immune Reconstitution After Alemtuzumab Therapy for Multiple Sclerosis Triggering Graves’ Orbitopathy: A Case Series

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2018English

Abnormalities in Iron Metabolism in Multiple Sclerosis

Canadian Journal of Neurological Sciences
MedicineNeurology
1989English

Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2013English

Adverse Events With Fatal Outcome Associated With Alemtuzumab Treatment in Multiple Sclerosis

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy